– Advertisement –
Emzor Pharmaceutical Industries Limited, one of Nigeria’s dominant domestic drugmakers, has successfully extended its debt maturity profile, tapping local capital markets to fund the final stretch of a pioneering industrial project that promises to transform regional drug supply chains.
The Lagos-based manufacturer closed the remaining 28% funding gap for Nigeria’s first active pharmaceutical ingredient (API) manufacturing plant after restructuring its balance sheet.
Long-term money, anchored by a recent NGN26.7 billion ($17.6 million) bond issuance, has been deployed to refinance volatile short-term loans and insulate the company from immediate liquidity shocks. Management expects the anti-malaria API facility to wrap up construction by Q4 2026, positioning it to pad corporate earnings starting in 2027.
The corporate pivot comes at a critical juncture for Nigerian manufacturers navigating severe macroeconomic headwinds, foreign exchange volatility, and escalating borrowing costs.
Top-Line Surge Masked by Sticky Costs
Emzor’s financial performance highlights the dual realities of operating in Africa’s most populous nation: robust top-line expansion fueled by nominal price adjustments, alongside tightening credit metrics under the weight of high interest rates.
Revenue surged 31.2% to NGN66.9 billion in the twelve months through December 31, 2025, bringing its five-year compound annual growth rate (CAGR) to a healthy 17.5%. The performance was driven by a combination of inflation-linked price hikes and a gradual recovery in product volumes.
Efficiencies from cost-containment measures and an improved sales mix lifted the company’s EBITDA margin to 22.7% in 2025, expanding further to 24.1% during the first four months of 2026.
The Credit View: Liquidity vs. Operational Cash Drag
Source link
Read Full Article by Bala Augie at moneycentral.com.ng
Source link
